Table 4.

Results of phase II clinical trials with bevacizumab in metastatic melanoma.

Author	Description	Regimen	Number of patients	Response rate (%)	Partial response (%)	Stable disease (%)	Median PFS (months)	Median OS (months)
Varker et al. [2007]	Previously treated	Bevacizumab	16				3	8.5
		Bevacizumab and IFN	16				3	10
González-Cao et al. [2008]	Previously treated	Bevacizumab and weekly paclitaxel	12	17	17	58	3.7	7.8
Perez et al. [2009]	Previously treated	Bevacizumab and weekly paclitaxel and carboplatin	53	17	17	57	6	12
Peyton et al. [2009]	Previously treated	Bevacizumab and everolimus	28	4	4	68	3.5
Si et al. [2009]	Previously treated acral	Bevacizumab and temozolomide and sorafenib	11	18	18	54.5
Wyman et al. [2007]	First line and Previously treated	Bevacizumab and erlotinib	29	9	9	22	3.2
Munzone et al. [2007]	First line	Bevacizumab and dacarbazine	8	20	20	40
Boasberg et al. [2009]	First line	Bevacizumab and nab-paclitaxel	41				6.25	91% (6 months)
								83% (12 months)
O’Day et al. [2009]	First line	Bevacizumab and paclitaxel and carboplatin	143	25.5	23.4	50.4	5.6	12.3
		Paclitaxel and carboplatin	71	16.4	14.9	37.4	4.2	8.6

IFN, interferon; OS, overall survival; PFS, progression-free survival.